Innovation Portfolio
Freie Universität Berlin
First Excellence university of the Berlin University Alliance (BUA), with internationally recognized strengths in humanities, social sciences, life sciences, and natural sciences. Strong interdisciplinary research in biodiversity, climate change, and high-performance technologies.
199
Patents
443
Inventors
151
Spin-offs
Patent Portfolio
Analysis of our organization's intellectual property assets
Patents by Technology Area
Portfolio Highlights
Total Patents
199
Recent Patent Publications (2025 & 2026)
13
Top Inventors
Patent Portfolio
Featured Technologies
Discover our latest patented technologies
Conjugation Product Comprising an Antigen Binding Moiety and a Mucin Binding Moiety
This patent describes a new type of conjugated biopharmaceutical in which an antigen binding moiety (such as an antibody that binds to viruses, bacteria, allergens, or sperm cells) is covalently linked to a mucin binding moiety. The mucin binding part enables the conjugate to adhere to mucus in the body (such as in the nose, respiratory tract, or reproductive system). This adjacency to mucus increases the binding efficacy of the antigen-binding portion, leading to better protection or therapeutic effects, for example in trapping pathogens or allergens at mucosal surfaces.
Coating Substance and Dual Polymer Coating Assembly
This patent describes a novel coating substance and dual-sided polymer-based coating assembly that can be applied to various substrates. The invention enables the creation of surfaces, such as filters or masks, that have both antibacterial and antiviral properties. It uses polymers with either positive or negative charges that are covalently bound to surfaces, ensuring long-term effectiveness against both viruses and bacteria. The dual-coating method applies different charged coatings to opposite sides of the substrate, preventing charge neutralization and maintaining broad-spectrum antimicrobial activity.
Compounds for the Inhibition of Kifc3, Methods of Making the Same, and Pharmaceutical Compositions Comprising the Same
This patent discloses a new class of compounds that selectively inhibit KIFC3, a specific motor protein involved in platelet production, and their pharmaceutical compositions. The invention focuses on treating diseases associated with abnormal KIFC3 function, such as neonatal thrombocytopenia, delayed platelet recovery following umbilical cord blood stem cell transplantation, and Down syndrome-associated myeloid neoplasms. The compounds can be administered to patients (including neonates) to increase endogenous platelet production, and are also applicable for ex vivo generation of platelets for transfusion.
Success Stories
Featured Spin-off Companies
Companies founded based on our organization's technologies
AVALY GmbH
AVALY GmbH offers data-driven, AI-powered software to help energy and infrastructure developers manage local social acceptance for projects such as wind and solar farms.
Caidera GmbH
Caidera GmbH is an AI-driven compliance platform for life sciences marketing, enabling faster and compliant content creation for regulated industries such as pharma, medtech, and biotech.
DistricTee GbR
Contact the Technology Transfer Office
The Freie Universität Berlin Technology Transfer team is ready to assist you with licensing inquiries and collaboration opportunities
Get in Touch
Phone
+49 30 838-63152
shift@forschung.fu-berlin.de
Address
Postanschrift: Kaiserswerther Str. 16-18, 14195 Berlin Büroanschrift: Altensteinstr. 40, 14195 Berlin Germany
Office Hours
Monday - Friday: 9:00 AM - 4:00 PM